Kevin B. Mahoney

Chief Executive Officer | University of Pennsylvania Health System, Penn Medicine

Kevin B. Mahoney is the CEO of the University of Pennsylvania Health System, guiding a wide network of hospitals, multispecialty centers, and outpatient sites across the region. Over three decades of leadership at Penn Medicine, he has championed initiatives that have reshaped how and where care is delivered, elevated the patient experience, and accelerated innovation. As part of this approach, Mahoney has overseen major capital investments, including the architecturally renowned Clifton Center for Medical Breakthroughs, and expanded Penn Medicine’s footprint to bring advanced care to more communities. He also co-founded the Fund for Health with the Wharton School, an initiative that invests in early-stage companies addressing the social determinants of health. Under his leadership, Penn Medicine—one of the world’s leading and America’s oldest academic medical centers—continues to translate discoveries in the lab into progress at the bedside, improving lives in Philadelphia and far beyond.

John “Jack” Lynch

Former 20 year CEO | Main Line Health

John J. (Jack) Lynch III served as President and CEO of Main Line Health from 2005 to 2025, leading a major suburban Philadelphia health system. The organization includes several acute care hospitals, a rehabilitation hospital, an addiction treatment center, a research institute, and a home care network. During his tenure, Lynch strengthened commitments to safety, quality, and equity while advancing supporting technologies. He also oversaw significant expansion, adding new facilities and health centers to better serve the region. Under his leadership, Main Line Health received national recognition, including major awards for quality and equity in care. Before joining Main Line Health, Lynch spent nearly 20 years with St. Luke’s Episcopal Health System in Houston, serving in top executive roles. He has served on numerous prominent healthcare and community boards.

Terry Gilliland

MD, CEO | Geisinger Health

Dr. Terry Gilliland was named Geisinger’s new president and CEO in 2024. He has extensive healthcare experience and has held senior executive roles spanning healthcare delivery and payer organizations. Most recently, Dr. Gilliland served as chief medical officer and chief science officer at Cogitativo, a healthcare-focused artificial intelligence and machine learning company. Prior to that, he served as executive vice president of Healthcare Quality and Affordability at Blue Shield of California and senior vice president and chief medical officer of Sentara Healthcare. Earlier in his career, Dr. Gilliland held various leadership roles at the Mid-Atlantic Permanente Medical Group and the Colorado Permanente Medical Group within Kaiser Permanente, in addition to being a practicing general surgeon.

Dr. Abigail Peterson

DMD, MPH, Assistant Professor | Clinical Community Oral Health Division of Community Oral Health Penn Medicine

Dr. Abby Peterson is an Assistant Professor of Clinical Community Oral Health at Penn Dental Medicine. She serves on the board of Kids Smiles, a nonprofit providing dental care to children in Philadelphia, where she previously practiced. She joined the Penn Dental Medicine faculty in 2020, teaching public health and clinical dentistry. Her work includes serving at Community Oral Health sites within the Department of Preventive & Restorative Science. She is actively involved in Penn Smiles, a school-based program in partnership with the School District of Philadelphia and community organizations. She also contributes to Bridging the Gaps, supporting community service and interprofessional training for students working with under-resourced communities.

Joanna Hart

MD, MSHP, Assistant Professor of Medicine and Medicine in Medical Ethics and Health Policy, Perelman School of Medicine

Dr. Joanna Hart is an Assistant Professor of Medicine and of Medical Ethics & Health Policy at the University of Pennsylvania and a core faculty member. She practices pulmonary and critical care medicine at the Michael J. Crescenz VA Medical Center and Penn Medicine. Her research focuses on improving the experience of serious illness for patients and their families. She emphasizes that serious illness affects families as well as patients and studies how to better integrate family into care. Her work also explores how clinicians and health systems can support complex decision-making. In 2019, she founded Penn LDI’s Rural Health and Policy working group to strengthen collaboration with rural communities and improve their health outcomes.

N. Benjamin Frederick

MD, Director, Global Health Center | Director, PA Area Health Education Center | Professor, Family & Community Medicine and Public Health Sciences and Humanities, Penn State Hershey Medical Center; Pennsylvania State University College of Medicine

Dr. Benjamin Fredrick is Director of the Pennsylvania Area Health Education Center (PA AHEC), leading a statewide network to strengthen the healthcare workforce in rural and underserved communities. His work focuses on training, recruitment, and retention strategies to address access gaps across Pennsylvania. He has contributed to state policy discussions, including legislative testimony on rural health. He also convened a Rural Medical Education Collaborative to address declining rural primary care. Under his leadership, PA AHEC helped develop the workforce component of Pennsylvania’s 2025 Rural Health Transformation grant proposal. He is also a Professor at Penn State College of Medicine and directs the Global Health Scholars Program.

Stephen Hahn

MD, CEO & Board Member | Nucleus RadioPharma

Dr. Stephen M. Hahn is the CEO of Nucleus RadioPharma, with more than two decades of leadership in biotechnology, government, healthcare strategy, oncology, and clinical research. He served as the 24th Commissioner of Food and Drugs at the U.S. Food and Drug Administration (FDA) from 2019 to 2021, overseeing regulatory efforts across therapeutics, vaccines, devices, diagnostics, and clinical trials. From 2021 to 2025, he was CEO of Harbinger Health, a cancer diagnostics biotechnology company. Prior to the FDA, he was chief medical executive at MD Anderson Cancer Center in Houston. He also served as deputy president and chief operating officer, overseeing daily operations, more than 21,000 employees, and a $5.2 billion budget. Earlier in his career, he held leadership roles in radiation oncology at MD Anderson and chaired the department at the University of Pennsylvania’s Perelman School of Medicine. His research has focused on tumor biology and treatment response, and he has authored more than 220 peer-reviewed publications.

Frederick Vogt

Ph.D., J.D., Iovance Interim CEO, President and General Counsel

Dr. Frederick Vogt joined Iovance in September 2016 as General Counsel and has served as Interim CEO and President since May 2021, as well as a board member since June 2024. He brings more than 20 years of experience in the pharmaceutical and biopharmaceutical industries. Before Iovance, he practiced law at Morgan, Lewis & Bockius, focusing on intellectual property and business law in the life sciences. Earlier, he spent 13 years at GlaxoSmithKline in scientific, management, and legal roles, contributing to the development and approval of several oncology and cardiovascular drugs including, Hycamtin®, Votrient®, Tafinlar®, and Mekinist®. He has authored over 70 publications, is a co-inventor on numerous patents, and is admitted to practice before multiple courts and the U.S. Patent and Trademark Office.

Ron Philip 

Board Member | City Therapeutics & Harmony Biosciences and advises several private biotechnology companies.

Ron Philip is a biotech and biopharma leader known for building and scaling innovative companies. He most recently served as President and CEO of Orbital Therapeutics, which was acquired by Bristol Myers Squibb. He currently sits on the boards of City Therapeutics and Harmony Biosciences and advises several private biotech firms. Earlier, he held leadership roles at Spark Therapeutics, ultimately becoming CEO and helping lead the launch of LUXTURNA®, the first FDA-approved gene therapy for a genetic disease. He also played a key role in Spark’s acquisition by Roche and its evolution into a fully integrated gene therapy company. Prior to that, he spent a decade at Pfizer and Wyeth in senior global leadership roles across strategy, business development, and regional operations. He began his career at Deloitte and Merck and remains active in the life sciences and Philadelphia communities through board service.

Roy Rosin 

MBA, Board Partner | First Round Capital

Roy Rosin is a Board Partner at First Round Capital, where he works with founders transforming healthcare and improving practice performance. The firm is known for backing major companies like Uber and Flatiron Health. He previously served as Chief Innovation Officer at Penn Medicine, leading efforts to design and implement new approaches to improve patient outcomes and experience. Before healthcare, he was Intuit’s first Vice President of Innovation, where he reshaped how the company developed new businesses. His work helped drive significant growth, with shareholder returns far exceeding the S&P 500. Earlier, he led the Quicken team to strong profitability and growth, reaching millions of users. Rosin now advises startups and health system leaders.

Jeff Marrazzo

Co-Founder & Former CEO | Spark Therapeutics

Jeff Marrazzo is the co-founder and former CEO of Spark Therapeutics, where he led the company from 2013 to 2022, building it into the world's first fully integrated commercial gene therapy company. Under his leadership, Spark launched the first FDA-approved gene therapy for a genetic disease in the U.S. and built an R&D portfolio spanning nine rare, genetic diseases. As CEO, Marrazzo raised $1 billion, created partnerships with two of the largest global pharmaceutical companies, and led Spark's $4.8 billion sale to Roche — a 100x return for its venture investors. By the time he stepped down, Spark boasted 850 employees and top industry workplace recognition. He now serves on several biotech and nonprofit boards, including as founding chair of Dispatch Bio, and co-founded the Marrazzo Family Foundation with his wife to foster creativity in Philadelphia youth.

Michelle Cully 

Ph.D. | Governor Shapiro’s office, PA Department of Community and Economic Development; Technology and Entrepreneurship 

Michelle Cully is the Life Sciences Economic Development Specialist for the Pennsylvania Department of Community and Economic Development (DCED), where she provides strategic guidance to statewide leadership on the life sciences industry. She leads initiatives to promote innovation and drive the growth of life sciences businesses across the Commonwealth. Michelle brings diverse product development experience spanning medtech, diagnostics, and AI-enabled tools, and holds a doctorate in Immunology from the University of Pennsylvania. She offers a perspective on how policy and public-private collaboration can strengthen and scale a more resilient life sciences ecosystem in Pennsylvania.

Paul Friel

State Representative | Pennsylvania 

Paul Friel is the State Representative of Pennsylvania’s 26th district in Chester County.  First elected in 2022, Paul serves on the Appropriations, Education, Energy, and Agriculture committees, is a founder and co-chair of the PA Competitiveness Caucus, and is member of the Life Science Caucus. Paul was also appointed by Governor Shapiro to serve on the 529 Tuition Account Program Advisory Board in 2023. Professionally, Paul served in a variety of senior management roles including CEO and draws on his diverse background having led retail, manufacturing, and environmental engineering organizations in his current role as a legislator.  Paul applies a practical, results-oriented mindset to the challenges facing Pennsylvania. He has earned the reputation as a leader who is rooted in collaboration, frequently working across the aisle and convening diverse workgroups to remove roadblocks and find common ground on complex policy issues in areas such as education, agriculture, and healthcare and energy.

Bridget Kosierowski

State Representative | Pennsylvania

Bridget Kosierowski is the State Representative for Pennsylvania’s 114th district. She built her career as a registered nurse, beginning at the Hospital of the University of Pennsylvania. She brings a practical, community-focused perspective and emphasizes strong convictions in public service. Elected in 2019, she became the first Democratic woman from Lackawanna County to serve as State Representative in over 55 years. Since then, she has helped secure more than $215 million for infrastructure and community revitalization. She has introduced legislation on the nursing licensure compact, student loan relief for nurses, patient safety act, education and healthcare. Bridget has also delivered over 20,000 constituent services and serves on the Appropriations, Health, Professional Licensure, Aging, and Insurance Committees. She also serves on a Legislative Task Force focused on drug recovery, a role informed by her 27 years of experience as a registered nurse.

Peter D. Quinn

DMD, MD | Professor of Oral & Maxillofacial Surgery/Pharmacology at Penn Dental Medicine

Dr. Peter Quinn is the Chief Physician Executive (Emeritus) of the Penn 
Medicine Medical Group (PMMG). He served as the Chair of the Department 
of Oral & Maxillofacial Surgery for 22 years in the University of Pennsylvania 
School of Dental Medicine and as Vice Dean for Professional Services in the 
Perelman School of Medicine for 11 years. Dr. Quinn has also served as the 
Senior Vice President of the Penn Health System overseeing the Clinical 
Practices of the University of Pennsylvania. His main clinical and research 
interest is in the field of alloplastic replacement of the temporomandibular 
joint. 

Eric Heil 

MBA | Mangaing Partner, Medical Excellence Capital | Chairman & CEO, Ladder Bio, Inc.

Eric Heil, is a venture capitalist and CEO with extensive experience in healthcare and life sciences. He is currently Managing Partner at Medical Excellence Capital, a $300M+ early-stage life science venture fund. He currently serves as Chairman and CEO of Ladder Bio and holds board positions at Nobias Therapeutics, GC Therapeutics. Heil is the cofounder and board chair of ProJenX, a company focused on ALS. Previously, he cofounded and led venture-backed companies including Upward Health and RightCare, the latter of which was acquired by naviHealth. He began his career in investing and consulting at Domain Associates, Easton Associates, and Bear Stearns.